Alogliptin
- Generic Name
- Alogliptin
- Brand Names
- Incresync, Kazano, Nesina, Oseni, Vipidia
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N5O2
- CAS Number
- 850649-61-5
- Unique Ingredient Identifier
- JHC049LO86
- Background
Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
- Indication
Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
- Conditions
- Interventions
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 458
- Registration Number
- NCT05782192
- Locations
- 🇨🇳
1. Sun Yat-sen Memorial Hospital, Sun Yat-sen University,, Guangzhou, Guangdong, China
Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive
- Conditions
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1293
- Registration Number
- NCT03794336
- Locations
- 🇨🇳
CHINA, China, China
A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants
- Conditions
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 72
- Registration Number
- NCT03501277
- Locations
- 🇷🇺
Non-governmental healthcare Institution Road Clinical Hospital at the station Yaroslavl JSC Russian Railways, Yaroslavl, Russian Federation
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Celltrion Pharm, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT03499704
- Locations
- 🇰🇷
The Catholic University of Korea, Bucheon, St. Marys Hospital, Bucheon-si, Gyeonggi-do, Korea, Republic of
🇰🇷Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of
🇰🇷The Catholic University of Korea, ST. Vincents Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of
Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 60
- Registration Number
- NCT03231709
- Locations
- 🇯🇵
OCROM Clinic, Suita, Osaka, Japan
🇯🇵ToCROM Clinic, Shinjuku, Tokyo, Japan
Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- Takeda
- Registration Number
- NCT03042325
Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 593
- Registration Number
- NCT02989649
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 27
- Registration Number
- NCT02771093
An Extension Study of PEAK Trial
- Conditions
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Kun-Ho Yoon
- Target Recruit Count
- 41
- Registration Number
- NCT02763007
- Locations
- 🇰🇷
Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of
Phase 1 Bioavailability Study of SYR-322MET
- Conditions
- Interventions
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24
- Registration Number
- NCT02508168
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.